PremiumRatingsGoodRx Holdings: Buy Rating Affirmed Amidst Promising Profit Growth and Strategic Leadership GoodRx price target raised to $4.75 from $4.25 at BofA GoodRx price target lowered to $8 from $9 at Wells Fargo PremiumThe FlyGoodRx sees FY25 revenue $810M-$840M, consensus $825.6M Notable companies reporting before tomorrow’s open GoodRx Holdings: Hold Rating Amid Leadership Changes and Modest Growth Expectations PremiumThe FlyGoodRx appoints interim CFO as Karsten Voermann resigns GoodRx price target lowered to $4.25 from $4.50 at BofA GoodRx Holdings CFO Resigns, Interim CFO Appointed 
